Sign In
Buy BIIB
$195.96
+7.13 (+3.78%)
At Close: Jun 03, 2026
Will New Drugs Help Biogen Surpass Q3 Earnings Estimates?
04:01pm, Thursday, 24'th Oct 2024
In the third quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.
Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
07:30am, Thursday, 24'th Oct 2024
CAMBRIDGE, Mass., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer's Disease (CTAD) annual confere
Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:08am, Wednesday, 23'rd Oct 2024
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
10:41am, Wednesday, 23'rd Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
09:35am, Tuesday, 22'nd Oct 2024
Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings.
Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
07:30am, Tuesday, 22'nd Oct 2024
CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the company will present a variety of new data from its felzartamab clinical development program at Kidney
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
03:34pm, Friday, 11'th Oct 2024
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-tim
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
01:18pm, Thursday, 10'th Oct 2024
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 3 Stocks Are Screaming Oversold: Seize the Opportunity
09:45am, Thursday, 10'th Oct 2024
The stock market's impressive and resilient performance in 2024, with the SPDR S&P 500 ETF NYSE: SPY up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks a
Biogen's stock bounces after FDA boost on kidney-transplant rejection treatment
08:32am, Wednesday, 09'th Oct 2024
Biogen stock was headed higher Wednesday, to bounce off an 11-year closing low, after the biotechnology company received positive news from regulators about its treatment for kidney-transplant rejecti
CAMBRIDGE, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough
CAMBRIDGE, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced detailed results from Part B and Part C of the Phase 2/3 DEVOTE study evaluating the safety and efficacy
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
10:45am, Monday, 07'th Oct 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324
11:30am, Friday, 27'th Sep 2024
Sage Therapeutics announces discontinuation of the collaboration agreement with Biogen related to SAGE-324 for essential tremor.
Biogen's Lupus Candidate Meets Key Goals in Phase III Study
01:01pm, Wednesday, 25'th Sep 2024
The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus erythematosus meets the primary endpoint.
